Double-blinded, randomized, placebo-controlled study to evaluate the effectiveness of sulphasalazine in preventing acute gastrointestinal complications due to radiotherapy-Reference-Cited by-同舟云学术

Double-blinded, randomized, placebo-controlled study to evaluate the effectiveness of sulphasalazine in preventing acute gastrointestinal complications due to radiotherapy

Published:2000-11 Issue:2 Volume:57 Page:125-129
ISSN:0167-8140
Container-title:Radiotherapy and Oncology
language:en
Short-container-title:Radiotherapy and Oncology

Author:

Kiliç Diclehan,Egehan İbrahim,Özenirler Seren,Dursun Ayşe

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology

Reference21 articles.

1. A randomized trial to assess the efficacy of 5-aminosalicylic acid for the prevention of radiation enteritis;Baughan;Clin Oncol,1993

2. The relationship between early and late gastrointestinal complications of radiotherapy for carcinoma of the cervix;Burne;Int J Radiat Oncol Biol Phys,1983

3. In vivo rectal inflammatory mediator changes with radiotherapy to the pelvis;Cole;Gut,1993

4. Genital tract, uterine cervix;Crook,1994

5. Correction for the use of the LENT-SOMA tables;Denekamp;Radiother Oncol,1996

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radiation Enteritis in Patients Receiving Abdominal Radiation Therapy;Complications of Cancer Therapy: Best Practices in Prevention and Management;2024

2. A Prospective Randomized Controlled Trial to Study the Role of Sulfasalazine in the Prevention of Acute Gastrointestinal Toxicities in Patients of Carcinoma of the Cervix Receiving Concurrent Chemoradiation;South Asian Journal of Cancer;2023-10-16

3. Combined radiation burn injuries: A note;Journal of Radiological Protection;2022-11-17

4. The Pathogenesis, Pathological Manifestation and Progress in Clinical Drug Research of Acute Radioactive Enteritis;Advances in Clinical Medicine;2022

5. Neoadjuvante und adjuvante Therapiekonzepte bei gastrointestinalen Tumoren: Prophylaxe und Therapiemanagement von Nebenwirkungen;Der Onkologe;2021-03-03